Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

PR Raghavan

Nanorx Inc., PO Box 131, Chappaqua, NY 10514, USA

Biography

Dr. PR Raghavan CEO of Nanorx INC has a Ph.D. in Organic Chemistry from Oregon State University(1979) and an M.S in Chemistry(1972) from I.I.T Mumbai, India.He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 15 US and International patents and another 15 pending patent applications
Publications

A Multi Gene Targeting Approach to Treating Liver Diseases with Metadichol®

Liver diseases are becoming a major health concern. In the developing countries it is due to microbial infection. In the rest of the developed world it is due to alcohol abuse. Chronic liver disease and cirrhosis are a significant health concern in western countries. It is the fifth most common cause of death, after heart disease, cancer, stroke, a... Read More»

PR Raghavan

: J Cytokine Biol 2019, 3: 126

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Top